Business Context and Reporting Period
Company: uniQure N.V.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: uniQure is a gene therapy company focused on developing single-dose treatments for rare and devastating diseases. Its lead program is AMT-130 for Huntington's disease. Other clinical candidates include AMT-260 (refractory mesial temporal lobe epilepsy), AMT-191 (Fabry disease), and AMT-162 (SOD1-ALS). The company divested its commercial manufacturing facility in Lexington, Massachusetts, to Genezen Holdings Inc. in July 2024.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenues | $16.1 million | $27.1 million |
| Net Loss | $(199.0) million | $(239.6) million |
| Research & Development Expenses | $(140.7) million | $(143.8) million |
| Selling, General & Administrative Expenses | $(65.5) million | $(52.7) million |
| Cash, Cash Equivalents & Investments | $622.5 million | $367.5 million |
| Long-Term Debt (Principal) | $50.0 million | $50.0 million |
| Accumulated Deficit | $(1,328.9) million | $(1,130.0) million |
Note: The filing text does not provide specific gross margin percentages as the company is pre-commercial for its own pipeline products. Revenue is primarily derived from royalties and collaboration fees related to HEMGENIX (licensed to CSL Behring).
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by $11.0 million (41%) compared to 2024. This was driven by a significant drop in collaboration revenue ($10.7 million decrease) following the divestiture of manufacturing activities to Genezen, partially offset by an increase in license revenue from HEMGENIX royalties ($5.8 million increase).
- Net Loss Improvement: Net loss narrowed by $40.6 million compared to 2024, primarily due to a $44.8 million improvement in non-operating items (driven by a $26.1 million foreign currency gain and a $12.4 million gain on pre-funded warrants) and a reduction in operating expenses.
- Liquidity Increase: Cash and investment securities increased by $255.0 million to $622.5 million, resulting from two follow-on public offerings in 2025 raising approximately $404.2 million in net proceeds.
- Debt Restructuring: In September 2025, the company amended its Hercules loan facility to a $175.0 million senior secured term loan. The interest rate floor was set at 9.45%.
Guidance, Outlook, and Material Risks
Regulatory Outlook (AMT-130)
The FDA has indicated that data from the Phase I/II studies of AMT-130 (Huntington's disease) are unlikely to provide the primary evidence required to support a Biologics License Application (BLA). In March 2026, following a Type A meeting, the FDA strongly recommended conducting a prospective, randomized, double-blind, sham surgery-controlled study. The company plans to request a Type B meeting in Q2 2026 to discuss study design.
Clinical Updates
- AMT-130 (Huntington's): Positive topline data announced in September 2025 showed statistically significant slowing of disease progression, but regulatory path remains uncertain pending FDA feedback.
- AMT-260 (Epilepsy): Enrollment of the first cohort completed in 2025; second cohort initiated.
- AMT-191 (Fabry): Enrollment of three cohorts completed. Dosing in mid- and high-dose cohorts paused pending evaluation of asymptomatic Grade 3 liver enzyme elevations (dose-limiting toxicity).
- AMT-162 (ALS): Enrollment voluntarily paused in September 2025 following a dose-limiting toxicity resulting in a serious adverse event.
Liquidity and Capital Resources
Management believes existing cash resources will fund operations into the second half of 2029. The company has access to an additional $100.0 million tranche of its Hercules loan facility, contingent on BLA approval of AMT-130 prior to June 2027.
Legal Proceedings
A class action lawsuit (Christopher Scocco v. uniQure N.V.) was filed in February 2026 alleging false and misleading statements regarding the Phase I/II study of AMT-130 and the timing of a potential BLA filing. The company intends to vigorously defend the action.
Key Facts for Investor Verification
- FDA Feedback on AMT-130: Verify the specific requirements for the recommended prospective, randomized, double-blind, sham surgery-controlled study and the estimated cost and timeline impact on the company's cash runway.
- Clinical Pauses: Monitor the resolution of the safety pauses in the AMT-191 (Fabry) and AMT-162 (ALS) programs and the potential impact on the overall pipeline valuation.
- Class Action Litigation: Track the status of the securities class action filed in February 2026 regarding AMT-130 disclosures.
- Debt Covenants: Review the covenants of the amended Hercules loan facility, specifically the market capitalization threshold ($1.2 billion) and cash balance requirements that could restrict operations if not met.
- Manufacturing Dependency: Assess the risks associated with reliance on Genezen for the manufacturing of HEMGENIX (supply obligations to CSL Behring) and clinical materials for the pipeline.